ERBB2 and neoplasm: Trastuzumab inhibits the homologous or heterologous dimerization of HER2 by specifically binding to the ECD IV, thereby blocking the activation of downstream signaling pathways and inhibiting the survival and angiogenesis of tumor cells [31].